Short Summary
The USPTO denied Comcast's request for Director review of the institution denial in IPR2024-00445, keeping the earlier decision that the patent was not instituted.
Detailed Summary
In IPR2024-00445 concerning U.S. Patent 10,135,682 B2, Comcast Cable Communications, LLC petitioned for Director review of the USPTO's earlier decision denying institution of the inter partes review. Director Katherine K. Vidal was recused, and Deputy Under Secretary Derrick Brent exercised delegated authority to consider the request. The Director ultimately denied the petition, thereby upholding the prior institution denial and leaving the patent unchallenged in the IPR proceeding.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Comcast Corporation et al. vs Entropic Communications LLC is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Aquestive Therapeutics, Inc.vsIono Pharma, LLC
Aquestive Therapeutics seeks Director Review of the PTAB’s denial of institution for its IPR against Iono Pharma’s epinephrine prodrug patent. Iono Pharma argues the request fails statutory standards and should be denied.
Juniper Networks, Inc.vsMonarch Networking Solutions LLC
The PTAB issued a final decision finding all 10 claims unpatentable based on obviousness over prior art references Li and Wu. The Board adopted the Petitioner's definition of 'domain,' which was crucial to establishing the combination of teachings from both sources.
Wella Operations US LLCvsOlaplex, Inc.
The USPTO Office issued a notice detailing multiple institution decisions across various IPR and PGR proceedings.
AZURITY PHARMACEUTICALS, INC.vsHelsinn Healthcare S.A.
Azurity has filed an IPR petition seeking cancellation of all 25 claims of Helsinn’s antiemetic patent (US 8,623,826) on the ground that the claims are obvious over multiple prior‑art references and that the asserted synergy is not unexpected.
Samsung Electronics Co., Ltd. et al.vsOptimum Imaging Technologies LLC
Samsung and Optimum Imaging Technologies have settled their dispute over U.S. Patent 7,612,805 and jointly moved to terminate the pending IPR.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.